Clavulanic acid-ticarcillin mixt.

583.58800

583.09305097

DTXSID10235588

268.11000

0.16850

768.3ºC

418.4ºC

Intravenous therapy with ticarcillin and clavulanate has been associated with elevations in serum aminotransferase levels in up to 10% of patients; however, these abnormalities were usually subclinical and self-limited. More important were rare instances of acute cholestatic liver injury arising several days to several weeks after initiation of ticarcillin-clavulanate. This hepatic injury resembled that caused by amoxicillin-clavulanate and was probably caused by the beta-lactamase inhibitor rather than the ticarcillin. However, too few cases were described in the literature to define the clinical characteristics of the idiosyncratic liver injury.

The combination of ticarcillin and clavulanate provides an extended-spectrum penicillin with a beta-lactamase inhibitor and was previously used to treat serious bacterial infections due to susceptible organisms. Given parenterally, ticarcillin-clavulanate can cause mild transient aminotransferase elevations, and therapy has been linked to instances of acute cholestatic liver disease similar to that described commonly with amoxicillin-clavulanate (Augmentin).

Antiinfective Agents

Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)|Endogenous substances and drugs that inhibit or block the activity of BETA-LACTAMASES. (See all compounds classified as beta-Lactamase Inhibitors.)|Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)

BRL 28500

Human Drugs -> FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) -> Active Ingredients